HSA (Singapore)

HSA (Health Sciences Authority) is Singapore's national competent authority for therapeutic products, medical devices, cellular + tissue + gene therapy products (CTGTPs), complementary health products + cosmetic products + Singapore's national blood service + national forensic science service. HSA was established in 2001 as a statutory board under the Ministry of Health (MOH), consolidating the former Centre for Drug Administration (CDA), Centre for Medical Device Regulation, Singapore Blood Transfusion Service + several forensic science entities. HSA's headquarters is in Outram, Singapore, with approximately 1,500 staff.

The HSA ecosystem includes:

• Health Products Regulation Group (HPRG) — the regulatory arm covering therapeutic products, medical devices, CTGTPs, complementary health products + cosmetic products.
• Blood Services Group (BSG) — Singapore's national blood service; operates blood-donor recruitment, processing + supply to hospitals.
• Applied Sciences Group (ASG) — national forensic science service; DNA, drugs of abuse, toxicology, chemistry, biology + crime-scene investigation.
• PRISM — HSA's online regulatory submission portal for therapeutic products, medical devices + CTGTPs.
• Ministry of Health (MOH) — parent ministry; HSA reports to MOH; MOH handles broader health policy + healthcare-system regulation.
• Health Promotion Board (HPB) — sister statutory board for public health promotion + disease prevention.
• Centre for Healthcare Innovation + Bioethics Advisory Committee — supporting bodies for regulatory innovation + ethics oversight.

Legal foundations are the Health Products Act 2007 (HPA — the umbrella law) + Health Products Regulations covering Therapeutic Products (2016), Medical Devices (2010), Cell Tissue and Gene Therapy Products / CTGTPs (2021), Complementary Health Products (2021) + Cosmetic Products (2007); the Medicines Act 1975 + Poisons Act 1938 + Misuse of Drugs Act + Sale of Drugs Act remain in force for specific scheduled substances + retail pharmacy contexts; the Human Biomedical Research Act 2015 covers clinical research + tissue banking.

HSA is a PIC/S member since November 2000 (one of the longest-standing Asian PIC/S members), an ICH Regulatory Member since June 2022 (the third Asian Regulatory Member after PMDA + MFDS), an Access Consortium / ACSS member alongside TGA + Health Canada + Swissmedic + MHRA, an MHRA International Recognition Procedure Reference Regulator since Jan 2024, an IMDRF Affiliate, an ASEAN Pharmaceutical Product Working Group + Medical Device Product Working Group lead participant + an MDSAP Affiliate Member.

• Class A — Lowest risk (e.g. surgical retractors, tongue depressors); Class A devices that are sterile or measuring require Class A Notification with QMS evidence; non-sterile / non-measuring Class A are exempt from product registration but require dealer's licence.
• Class B — Low-moderate risk (e.g. hypodermic needles, electrocardiographs).
• Class C — Moderate-high risk (e.g. lung ventilators, infusion pumps).
• Class D — Highest risk (e.g. heart valves, implantable defibrillators).
• Classification substantively aligned with EU MDR + GHTF / IMDRF principles — 22 rules across non-IVD device classification.
• Registration pathways — Full Evaluation Route, Abridged Evaluation Route (for devices approved by reference regulators), Expedited Class C/D Evaluation Route (for devices approved by 2+ reference regulators), Immediate Class C/D Registration Route (for devices approved by ALL reference regulators).
• Reference regulators for devices — Australia TGA, Canada Health Canada, Japan PMDA, EU Notified Bodies, US FDA.
• QMS — ISO 13485:2016; MDSAP audit reports accepted as Singapore QMS evidence; HSA on-site audits + Notified Body audits also accepted depending on route.
• Singapore Authorised Representative — foreign manufacturers must designate a Singapore-registered Registrant (Singapore Authorised Representative equivalent) who holds the dealer's licence + registers products.
• Dealer's licence — required for any party importing, manufacturing or wholesaling medical devices in Singapore; covers Importer's Licence, Manufacturer's Licence + Wholesaler's Licence depending on activities.
• Singapore UDI — HSA UDI implementation progressively rolling out; aligned with IMDRF UDI Guidance + GS1 / HIBCC / ICCBBA recognised as issuing entities.
• IVD classification — Class A / B / C / D substantively aligned with IVDR principles; HSA-specific guidance + classification rules.
• Field Safety Corrective Action (FSCA) — HSA FSCA reporting + Field Safety Notice (FSN) framework substantively aligned with EU MDR + IMDRF.

• CTGTP framework — Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021; effective 1 Mar 2021; created a dedicated CTGTP framework distinct from standard therapeutic products + medical devices.
• Scope — somatic cell therapy products, gene therapy products, tissue-engineered products + combinations; both autologous + allogeneic.
• Classification — Class 1 CTGTP (more substantial manipulation + non-homologous use) + Class 2 CTGTP (minimal manipulation + homologous use).
• Hospital exemption for Class 2 — qualifying hospitals can perform Class 2 CTGTP procedures under reduced regulatory burden subject to specific conditions (single-clinician oversight, no commercialisation).
• Class 1 product registration — full HSA product registration with comparability + clinical + non-clinical + CMC requirements substantively aligned with FDA / EMA ATMP / Japan regenerative-medicine frameworks.
• GMP for CTGTPs — HSA GMP CTGTP Guidance substantively aligned with PIC/S Annex 2A / 2B + EU GMP Annex 2A + FDA 21 CFR 1271.
• Singapore CTGTP ecosystem — substantial public + private investment in cell + gene therapy manufacturing; A*STAR Bioprocessing Technology Institute, Bioprocessing Technology Pilot Plant + multiple commercial CTGTP CMOs.
• Tissue banking — Human Biomedical Research Act 2015 + HSA CTGTP framework for human tissue handling, banking + research use.
• International alignment — HSA participating in Bispecific Antibodies + Multispecific Therapeutics + IMDRF + ICH cell + gene therapy working groups.

• HSA GMP — substantively aligned with PIC/S GMP Guide + ICH Q7 / Q9 / Q10; HSA Guidance + Annexes parallel PIC/S Annexes.
• HSA GDP — Singapore's Good Distribution Practice for therapeutic products + medical devices; substantively aligned with PIC/S GDP Guide.
• PIC/S Member since Nov 2000 — one of the longest-standing Asian PIC/S members; full reliance under PIC/S MoU.
• Reference Regulator network — HSA recognises Reference Regulators (FDA, EMA, EU national, Health Canada, TGA, MHRA, Swissmedic, PMDA + others) for both product authorisation reliance + GMP-evidence reliance.
• Overseas inspections — HSA conducts overseas inspections of foreign sites supplying Singapore; risk-based programme prioritising new MA applications + biologics + sterile products + APIs.
• Data integrity — HSA Data Integrity Guideline substantively aligned with PIC/S PI 041 + MHRA + WHO + FDA; ALCOA+ + audit-trail + computerised-systems expectations.
• MDSAP — HSA Affiliate Member; MDSAP audit reports accepted as Singapore device QMS evidence.
• ASEAN GMP harmonisation — HSA is a leading participant in ASEAN-PPWG harmonisation including ASEAN GMP guidance + mutual reliance arrangements within ASEAN.
• Inspection findings + remediation — HSA Inspection Reports + Warning Letters + manufacturing-licence suspension; published market actions on HSA portal.

• Adverse Drug Reaction (ADR) reporting — HSA Vigilance Branch operates the national ADR + medical-device adverse-event reporting system; integrated with WHO VigiBase via UMC Uppsala.
• ICSR reporting — Serious unexpected ADRs within 15 calendar days; non-serious in periodic reports + PSURs per ICH E2D + HSA Vigilance Guidance.
• PSUR — periodic safety update reports per ICH E2C(R2); harmonised with EU + ICH PSUR cycle.
• Risk Management Plan (RMP) — required for new active substances + biosimilars + new significant indications; per ICH E2E + HSA RMP guidance.
• Singapore Pharmacovigilance Officer — local pharmacovigilance contact required for Singapore MAH / Registrant.
• Medical device adverse-event reporting — HSA Field Safety Reports + FSCA / FSN framework substantively aligned with EU MDR vigilance.
• Healthcare-professional + consumer reporting — HSA Yellow-Form-equivalent + online reporting via HSA portal; broad reporter access.
• Recall — HSA-coordinated recall framework with importers + distributors + healthcare institutions.
• Drug Shortages — HSA Drug Shortage Reporting System; MAHs / Registrants required to report shortages of essential medicines.
• HSA Safety Communications — HSA Notices + Safety Alerts published on HSA portal + distributed to healthcare professionals.

• ICH Regulatory Member since Jun 2022 — third Asian Regulatory Member after PMDA + MFDS; HSA contributes to ICH Working Groups.
• PIC/S Member since Nov 2000 — longest-standing Asian PIC/S member alongside Australia + Malaysia.
• Access Consortium / ACSS — member alongside TGA + Health Canada + Swissmedic + MHRA; multilateral medicines + devices regulatory cooperation including joint scientific assessment + work-sharing.
• MHRA International Recognition Procedure — HSA is one of seven IRP Reference Regulators since Jan 2024.
• MDSAP Affiliate Member — MDSAP audit reports accepted for Singapore device QMS evidence.
• ASEAN — HSA leads ASEAN Pharmaceutical Product Working Group (PPWG) + Medical Device Product Working Group (MDPWG); ASEAN Common Technical Dossier + ASEAN harmonisation initiatives.
• IMDRF Affiliate — active on UDI, SaMD, AI / ML, QMS work products.
• ICMRA — active member contributing on pandemic preparedness, supply chain, regulatory innovation.
• WHO collaboration — HSA contributes to WHO PQ, WHO-Listed Authority framework + Collaborative Registration Procedure.
• Bilateral MoUs — HSA holds MoUs with FDA, EMA national authorities, Health Canada, TGA, MHRA, PMDA, MFDS + many others; tight regional cooperation with ASEAN-PPWG + MDPWG counterparts.
• APEC Regulatory Harmonization Steering Committee (RHSC) — HSA active member.

• Singapore Registrant / Authorised Representative not properly designated for therapeutic products or medical devices — application rejected at PRISM intake.
• Dealer's licence (Importer / Manufacturer / Wholesaler) not in place or scope mismatched — market placement blocked.
• Reference-regulator basis for Abridged / Verification / Expedited route not properly documented — applicants pushed back to Full Evaluation with substantial extra cost + time.
• PRISM eCTD submission errors — module structure non-compliance, missing Module 1 Singapore-specific elements.
• Singapore-specific labelling + IFU non-compliant — English language + Singapore-required content + HAS contact details.
• Reference-regulator assessment report not provided in full — partial assessment provided rather than the full Day-0 to Day-X assessment; Abridged review reverts to Full.
• Pharmacovigilance reporting timelines missed — Singapore Pharmacovigilance Officer enforcement.
• Data integrity findings — backdating, audit-trail disabled, shared logins, uncontrolled spreadsheets used as raw data.
• Sterile / aseptic process gaps — HSA inspectorate alignment with EU GMP Annex 1 (2022 revision) creates new expectations + frequent findings.
• MDSAP audit-report packaging gap — HSA accepts MDSAP but requires the full audit report + non-conformity closures.
• Singapore UDI database gaps — UDI-DI mismatch with HSA medical-device database, packaging-hierarchy errors.
• CTGTP framework confusion — applicants assuming standard therapeutic-product or medical-device pathway applies to CTGTPs without invoking the dedicated CTGTP Regulations 2021.
• Hospital exemption (Class 2 CTGTP) misapplication — applicants attempting commercialisation under hospital exemption.
• Complementary Health Product vs Therapeutic Product classification confusion — products attempting CHP route when they meet therapeutic-product definition.
• Access Consortium / ACSS work-sharing eligibility gap — applicants applying for parallel review without meeting all ACSS criteria.

V5 Ultimate provides the operational infrastructure Singapore + foreign-supplier sites need for Health Products Act + HSA Guidance compliance + HSA readiness.

• HSA GMP control framework — PIC/S-aligned controls (clean rooms, aseptic process, environmental monitoring, EU GMP Annex 1 2022 alignment, computerised systems) with ALCOA+ data-integrity + HSA Data Integrity Guideline alignment.
• Singapore Registrant / Authorised Representative + Dealer's Licence workflow — Registrant designation, Importer / Manufacturer / Wholesaler licence scope management, foreign-manufacturer QMS-evidence packaging.
• PRISM submission packaging — eCTD-aligned dossier structure with Singapore Module 1 specifics, reference-regulator assessment-report packaging for Abridged / Verification / Expedited routes.
• Reference-regulator bridging — FDA / EMA / Health Canada / TGA / MHRA / Swissmedic / PMDA assessment-report packaging for HSA Abridged + Verification + Expedited routes; Singapore-specific data overlay.
• Access Consortium / ACSS work-sharing — for products eligible for parallel HSA + TGA + Health Canada + Swissmedic + MHRA review; joint scientific assessment packaging.
• MHRA IRP reverse-direction bridging — for HSA approvals being bridged to UK MA via MHRA IRP Route A / B.
• Medical Device registration workflow — Class A-D classification, Full / Abridged / Expedited / Immediate registration route management, MDSAP + ISO 13485 audit-report packaging.
• Singapore UDI — UDI-DI assignment + UDI-PI lifecycle + HSA medical-device database submission + IMDRF UDI alignment for dual-market companies.
• CTGTP workflow — Class 1 vs Class 2 classification, hospital-exemption tracking, GMP CTGTP Annex compliance for cell + gene therapy + tissue-engineered products.
• Pharmacovigilance — E2B(R3) ICSR generation, 15-day SUSAR timeline, PSUR / RMP packaging, Singapore Pharmacovigilance Officer workflow.
• Medical device vigilance — FSCA + FSN reporting per HSA framework + IMDRF alignment; UDI-linked surveillance.
• ASEAN dual-market workflow — for companies operating across ASEAN, V5 surfaces ASEAN-PPWG harmonised dossier-element reuse alongside Singapore-specific extensions.